Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;56(4):445-6.
doi: 10.4103/0019-5154.84735.

Effect of 0.1% tacrolimus ointment in localized vitiligo: an open uncontrolled trial

K Bhuvana  1 , N Sarala, Gurcharan Singh, T N Kumar
Affiliations

Effect of 0.1% tacrolimus ointment in localized vitiligo: an open uncontrolled trial

K Bhuvana et al. Indian J Dermatol. 2011 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Eyelids before treatment; (b) eyelids 3 months after treatment
See this image and copyright information in PMC

References

    1. Ortonne JP, Bahadoran P, Fitzpatrick TB, Mosher DB, Hori Y. Hypomelanoses and Hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick's Dermatology in Medicine. 6th ed. New York: McGraw Hill; 2003. pp. 839–47.
    1. Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: The vitiligo area scoring index. Arch Dermatol. 2004;140:677–83. - PubMed
    1. Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol. 2004;29:589–92. - PubMed
    1. Lepe V, Moncada B, Caastanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139:581–85. - PubMed
    1. Kostovic K, Pasic A. New treatment modalities for vitiligo: Focus on topical immunomodulators. Drugs. 2005;65:447–59. - PubMed